Next Article in Journal
Unfolding Role of a Danger Molecule Adenosine Signaling in Modulation of Microbial Infection and Host Cell Response
Next Article in Special Issue
Stress-Activated Protein Kinases in Spinal Cord Injury: Focus on Roles of p38
Previous Article in Journal
Introduction of Exogenous HSV-TK Suicide Gene Increases Safety of Keratinocyte-Derived Induced Pluripotent Stem Cells by Providing Genetic “Emergency Exit” Switch
Open AccessArticle

FM19G11 and Ependymal Progenitor/Stem Cell Combinatory Treatment Enhances Neuronal Preservation and Oligodendrogenesis after Severe Spinal Cord Injury

1
Neuronal and Tissue Regeneration Laboratory, Príncipe Felipe Research Center, 46012 Valencia, Spain
2
Stem Cell Therapies in Neurodegenerative Diseases Laboratory, Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(1), 200; https://doi.org/10.3390/ijms19010200
Received: 24 September 2017 / Revised: 2 January 2018 / Accepted: 5 January 2018 / Published: 9 January 2018
(This article belongs to the Special Issue Therapeutic Strategies to Spinal Cord Injury)
Spinal cord injury (SCI) suffers from a lack of effective therapeutic strategies. We have previously shown that individual therapeutic strategies, transplantation of ependymal stem/progenitor cells of the spinal cord after injury (epSPCi) or FM19G11 pharmacological treatment, induce moderate functional recovery after SCI. Here, the combination of treatments has been assayed for functional and histological analysis. Immediately after severe SCI, one million epSPCi were intramedullary injected, and the FM19G11 compound or dimethyl sulfoxide (DMSO) (as the vehicle control) was administrated via intrathecal catheterization. The combination of treatments, epSPCi and FM19G11, improves locomotor tasks compared to the control group, but did not significantly improve the Basso, Beattie, Bresnahan (BBB) scores for locomotor analysis in comparison with the individual treatments. However, the histological analysis of the spinal cord tissues, two months after SCI and treatments, demonstrated that when we treat the animals with both epSPCi and FM19G11, an improved environment for neuronal preservation was generated by reduction of the glial scar extension. The combinatorial treatment also contributes to enhancing the oligodendrocyte precursor cells by inducing the expression of Olig1 in vivo. These results suggest that a combination of therapies may be an exciting new therapeutic treatment for more efficient neuronal activity recovery after severe SCI. View Full-Text
Keywords: FM19G11; spinal cord injury; ependymal progenitor stem cells; oligodendrogenesis; locomotion; neuronal regeneration; axon growth FM19G11; spinal cord injury; ependymal progenitor stem cells; oligodendrogenesis; locomotion; neuronal regeneration; axon growth
Show Figures

Figure 1

MDPI and ACS Style

Alastrue-Agudo, A.; Rodriguez-Jimenez, F.J.; Mocholi, E.L.; De Giorgio, F.; Erceg, S.; Moreno-Manzano, V. FM19G11 and Ependymal Progenitor/Stem Cell Combinatory Treatment Enhances Neuronal Preservation and Oligodendrogenesis after Severe Spinal Cord Injury. Int. J. Mol. Sci. 2018, 19, 200.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop